Navigation Links
Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
Date:3/13/2013

SOLANA BEACH, Calif., March 13, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a development stage specialty pharmaceutical Company focused on the commercial development of compounded drug formulations, announced today that the underwriter, MDB Capital Group LLC, exercised its over-allotment option to purchase an additional 276,000 shares of the Company's common stock at a price of $5.25 per share, for gross proceeds of approximately $1.45 million. The net cash proceeds of the over-allotment to the Company, after deducting underwriting discounts and commissions and estimated offering expenses, is expected to be approximately $1.33 million. The exercise of the over-allotment option brings the total approximate offering size of gross proceeds to $11.11 million.

This announcement shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The offering will be made only by means of a prospectus, copies of which may be obtained from MDB Capital Group LLC, 401 Wilshire Boulevard, Suite 1020, Santa Monica, CA 90401, (310) 526-5000.

About Imprimis Pharmaceuticals, Inc.
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a specialty pharmaceutical Company focused on the commercial development of compounded drug formulations. Through our exclusive, strategic relationship with Professional Compounding Centers of America (PCCA), the largest compounding pharmacy organization in North America, Imprimis expects to use its proprietary Accudel drug delivery technology, proprietary formulations, and market data, to identify pharmaceutical development opportunities where there is a significant unmet medical need. In addition, Imprimis is internally developing non-invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. Impracor, our lead Phase III pain product candidate, utilizes the Accudel platform technology to deliver the active drug, Ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications.

For more information on Imprimis Pharmaceuticals, Inc., please visit: http://imprimispharma.com/

About MDB Capital Group
MDB Capital Group LLC is an investment banking and institutional research firm focused exclusively on companies possessing or seeking to develop market-changing, disruptive technologies and intellectual property. For more information on MDB Capital Group, visit www.mdb.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to close the offering, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, our ability to raise additional funding when necessary, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no  obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact: Josh Berg
Imprimis Pharmaceuticals, Inc.
(858) 704-4040


'/>"/>
SOURCE Imprimis Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
2. Imprimis Announces Key Leadership Appointments
3. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
4. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
5. Imprimis to Begin New Study of Its Topical Analgesic Drug
6. Imprimis Names Two Experts To Its Science And Regulatory Board
7. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
8. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
9. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
10. Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23, 2017 Varias proteínas ... enal) y el riesgo de diálisis ... pabetalone    Resverlogix Corp. ("Resverlogix" o ... de un ensayo en fase 1 con sede en ... (renal) severa. Los datos demostraron unos resultados importantes en ...
(Date:1/23/2017)... , January 23, 2017 A new Transparency ... Market was valued at US$0.53 bn in 2013 and is ... strong 17.50% CAGR between 2014 and 2022. The title of the ... Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), ...
(Date:1/23/2017)... 2017  ResMed (NYSE : RMD), BMC (Pékin, Chine) et ... aujourd,hui qu,ils se sont mis d,accord sur le règlement ... BMC et 3B seront autorisés à vendre leurs produits ... et ResMed effectuera le paiement de la décision en ... de Floride entre les deux parties. Le règlement n,inclut ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 23, 2017 , ... Moisture measurement is a necessary process ... paramount to success. Selecting an inappropriate measurement method can cause costly errors, and ... same equipment. Rare or expensive substances are wasted and production may even be ...
(Date:1/23/2017)... ... 2017 , ... "ProRandom is a set of camera tools that allow video editors to integrate ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, ... video footage. ProRandom works by using a virtual camera to create the illusion of ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... Foundation (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the ... (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, ...
(Date:1/23/2017)... ... ... Inn at the Mill”: a story of love and redemption, hope and uncertainty as ... content. , “The Inn at the Mill” is the creation of published author, Lois ... is now living in Berks County on Crow Hill. The inn, the mill ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and ... resources have been developed for use by nutrition educators and influencers within ...
Breaking Medicine News(10 mins):